Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Earnings Routine −

Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update

Rakovina Therapeutics Confirms Accelerating Burn Rate and Critical Cash Position Despite Financing

By The Northwire Desk — AI Analysis Apr 30, 2026 · 17:10 RKV · 0.115 Rakovina Therapeutics Inc.
Executive Summary
  • Financial Results: Rakovina reported a full-year net loss of $8.68M for FY 2025, more than doubling from $4.07M in FY 2024. Q4 net loss was $1.89M.
  • Cash Position: As of December 31, 2025, cash and equivalents stood at only $298,758 with a working capital deficit of $2.15M.
  • Financing Activity: Closed a non-brokered private placement of convertible debenture units for $1M gross proceeds on March 5, 2026. Restructured approximately $1.59M in existing debentures via share settlements and replacement debentures.
  • Pipeline Progress: Three AI-powered programs (kt-5000, kt-3283, kt-2000) are advancing toward milestones in 2026. IND-enabling studies for kt-5000 targeted for H2 2026.
  • Corporate Updates: Completed a 10-to-1 share consolidation on June 24, 2025. New CEO Kim Oishi appointed in January 2026.
Material Impact
  • Cash Runway Risk: The cash balance of $298k at year-end combined with an $8.68M annual burn rate indicates a critical liquidity gap that requires immediate future financing to reach IND milestones in H2 2026.
  • Dilution Pressure: Recent financing involved issuing warrants ($1M raised = ~2M warrants) and share settlements for debt, increasing the fully diluted share count and potential selling pressure at $0.20 strike price.
  • Loss Acceleration: The doubling of net losses year-over-year signals increased R&D spend without corresponding revenue, raising concerns about capital efficiency.
  • Market Reaction: Stock price has declined significantly from July 2025 highs ($0.82) to current levels ($0.11), reflecting market pricing in the high burn rate and dilution risk.
RKV · Price
Company Overview
  • Company: Rakovina Therapeutics Inc., focused on AI-driven drug discovery for oncology.
  • Flagship Project: kt-5000 (ATR-mTOR inhibitor). Designed using Variational AI's Enki platform to target PTEN-deficient cancers with CNS penetration.
  • Secondary Projects: kt-3283 (PARP/HDAC inhibitor) utilizing NanoPalm LNP formulation; kt-2000 (PARP inhibitor).
  • Development Stage: Preclinical. IND-enabling studies targeted for H2 2026.
Read the original news release →

More from Rakovina Therapeutics Inc.

Jun 01, 2026 · 17:00

Rakovina Cuts Costs and Restructures Debt, But Pre-Revenue Burn Rate Demands Immediate Capital Infusion

Earnings Apr 22, 2026 · 04:00

AI-Driven Oncology Pipeline Validates Preclinical Efficacy

Other Mar 23, 2026 · 04:00

Rakovina Therapeutics to Present New Data at the AACR Annual Meeting 2026 - World's Premier Cancer Research Forum

Other Mar 12, 2026 · 15:28

Rakovina Therapeutics Announces Extension of Non-Brokered Private Placement

Financings Mar 05, 2026 · 20:50

Rakovina closes $1-million debenture unit financing

Financings Mar 05, 2026 · 20:06

Rakovina Announces Closing of $1 Million Debenture Unit Private Placement and Debt Settlement Agreements

Financings